Under Trump, FDA Seeks To Abandon Expert Reviews of New Drugs
Advisory committee meetings help FDA scientists make decisions and increase public understanding of drug regulation, and abandoning them doesn鈥檛 make sense, former officials said.
Showing 21 - 40 of 119
-
-
Changes at NIH Give Political Appointees Greater Power To Fund or Block Research
The National Institutes of Health鈥檚 long-held standard of peer review for grantmaking has been subverted by President Donald Trump and NIH Director Jay Bhattacharya, who gave unprecedented power to politicos, NIH workers say.
By Arthur Allen -
FTC Has Long Said Products Must Back Up Health Claims. A MAHA Lawsuit Would Upend That.
Xlear, a maker of xylitol gum, has sued the Federal Trade Commission, saying the onus should be on government to prove that ingredients don鈥檛 live up to advertised claims. RFK Jr.鈥檚 鈥渕edical freedom鈥 allies have rallied to the cause.
By Arthur Allen -
World鈥檚 Premier Cancer Institute Faces Crippling Cuts and Chaos
After spearheading a 34% cut in cancer mortality, the National Cancer Institute at the NIH is bleeding resources and staff and could see its budget cut by nearly 40%.
By Rachana Pradhan and Arthur Allen -
Kennedy鈥檚 Vaccine Advisers Sow Doubts as Scientists Protest US Pivot on Shots
A new vaccine advisory panel appointed by the HHS secretary, a longtime anti-vaccine activist, reflected his unsupported claims about the safety of childhood inoculations.
By Arthur Allen and Sam Whitehead -
What RFK Jr. Isn鈥檛 Talking About: How To Make Vaccines Safer
Vaccines are under fire from the top of the Trump administration. Federal programs to monitor them and make them safer have always been underfunded.
By Arthur Allen -
Two Patients Faced Chemo. The One Who Survived Demanded a Test To See if It Was Safe.
Worried that President Donald Trump鈥檚 FDA might not act, a panel of cancer experts recommended that doctors consider testing before dosing patients with a commonly used but sometimes deadly cancer drug. It came too late for many patients.
By Arthur Allen -
Pharmacists Stockpile Most Common Drugs on Chance of Targeted Trump Tariffs
While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs 鈥 which account for 90% of U.S. prescriptions 鈥 see trouble ahead for patients.
By Jackie Forti茅r and Arthur Allen -
Trump Team鈥檚 $500 Million Bet on Old Vaccine Technology Puzzles Scientists
Secretary Robert F. Kennedy Jr.鈥檚 HHS said an enormous, noncompetitive flu vaccine development grant to two favored NIH leaders would ensure 鈥渢ransparency, effectiveness, and comprehensive preparedness.鈥 But their vaccine is in early stages, relies on old technology, and is just one of scores of similar efforts.
By Arthur Allen -
Measles Misinformation Is on the Rise 鈥 And Americans Are Hearing It, Survey Finds
Attitudes about a debunked link between measles vaccines and autism haven鈥檛 budged that much. But there鈥檚 a sharp partisan divide over whether the vaccine is safe.
By Arthur Allen -
Trump HHS Eliminates Office That Sets Poverty Levels Tied to Benefits for at Least 80 Million People
Recent cuts eliminated a small, specialized workforce that sets the poverty standards determining who is eligible for Medicaid as well as assistance with food, home heating, child care, and more.
By Arthur Allen -
What鈥檚 Lost: Trump Whacks Tiny Agency That Works To Make the Nation’s Health Care Safer
The Agency for Healthcare Research and Quality has helped improve health care safety in a country where thousands die of medical errors each year. It was effectively dissolved Tuesday.
By Arthur Allen -
Scientists Say NIH Officials Told Them To Scrub mRNA References on Grants
Two senior scientists say National Institutes of Health officials advised them to remove references to mRNA vaccines in grant applications, and they fear the Trump administration will abandon a promising field of medical research.
By Arthur Allen -
Marty Makary, Often Wrong as Pandemic Critic, Is Poised To Lead the FDA He Railed Against
Should Marty Makary take the reins at the FDA, transitioning from gadfly to the head of an agency that regulates a fifth of the U.S. economy, he would have to engage in the thorny challenges of governing.
By Arthur Allen -
With RFK Jr. in Charge, Supplement Makers See Chance To Cash In
The FDA is already limited in policing claims of health benefits by makers of supplements and herbal remedies 鈥 a $70 billion industry. Get ready for even less regulation.
By Arthur Allen -
The Covid 鈥楥ontrarians鈥 Are in Power. We Still Haven鈥檛 Hashed Out Whether They Were Right.
Jay Bhattacharya, nominated to lead the National Institutes of Health, opposed most covid mandates. Without an honest public debate about what worked and what didn鈥檛, public health experts say, we鈥檙e even less prepared for the next pandemic.
By Arthur Allen -
-
What RFK Jr. Might Face in His Nomination Hearings This Week
Two Senate committees are expected to question Robert F. Kennedy Jr. on how his disproven views of science and medicine qualify him to run the $1.7 trillion, 80,000-employee federal health system.
By Arthur Allen -
How a Duty To Spend Wisely on Worker Benefits Could Loosen PBMs鈥 Grip on Drug Prices
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the 鈥淏ig Three鈥 PBMs 鈥 or force them to change.
By Arthur Allen -
How Measles, Whooping Cough, and Worse Could Roar Back on RFK Jr.鈥檚 Watch
Inoculation campaigns that protect children and adults from dangerous diseases rely on a delicate web of state and federal laws and programs. If senior officials cast doubt on vaccine safety, the whole system might collapse, especially in red states.
By Arthur Allen
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: